Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. August 2021 07:00 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference

NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
02. August 2021 07:30 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma

NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
02. August 2021 07:00 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentera Therapeutics Announces Closing of $75 Million Series B Financing

SHANGHAI, China, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentera Therapeutics, a clinical-stage biopharmaceutical company with headquarters in Shanghai, China, today announced the successful completion of...
01. Juli 2021 16:01 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
28. Juni 2021 21:09 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock

NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
28. Juni 2021 16:18 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock

NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
28. Juni 2021 07:00 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated

Reports additional ZN-c3 Phase 1 interim monotherapy data, demonstrating increased tumor reduction and durability in the exceptional responder population, as well as newly confirmed responses and an...
28. Mai 2021 07:00 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference

NEW YORK and SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
17. Mai 2021 07:00 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and Exceptional Responses in heavily pre-treated...
12. April 2021 07:00 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor

NEW YORK and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...

Vorherige Seite